Genprex
GNPX
9 hedge funds and large institutions have $13K invested in Genprex in 2025 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 7 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
0.01% more ownership
Funds ownership: 0% → 0.01% (+0.01%)
31% less funds holding
Funds holding: 13 → 9 (-4)
57% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 7
94% less capital invested
Capital invested by funds: $230K → $13K (-$217K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$20.3K |
| 2 |
MWA
Miller Wealth Advisors
Ridgeway,
Colorado
|
+$7.74K |
| 3 |
Jones Financial Companies
Des Peres,
Missouri
|
+$6.75K |
| 4 |
CVM
Cheviot Value Management
Beverly Hills,
California
|
+$6.33K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
+$422 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$73.2K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$57.6K |
| 3 |
Jane Street
New York
|
-$34.8K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$27.8K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$20.1K |
GNPX Hedge Fund Activity: Q4 2025 in Review
9 of the 8,245 institutional investors tracked by Wall St. Rank reported a position in Genprex (GNPX) for Q4 2025, worth a combined $13K — down 94% from $230K a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of GNPX and 3 opened new positions — a net loss of 4 holders — while 1 trimmed existing stakes and 2 added.
The largest buyer was Tower Research Capital (TRC), adding an estimated $20.3K. The largest seller was Vanguard Group, exiting entirely with an estimated $73.2K sold.
- 9 institutional investors held Genprex (GNPX) as of Q4 2025, down from 13 in Q3 2025.
- Funds reported $13K of Genprex stock for Q4 2025, down 94% quarter-over-quarter.
- 3 funds opened new Genprex positions in Q4 2025 and 7 closed out, a net change of -4 holders.
- The largest Genprex buyer in Q4 2025 was Tower Research Capital (TRC), an estimated $20.3K added.
- The largest Genprex seller in Q4 2025 was Vanguard Group, an estimated $73.2K sold.
Based on aggregated 13F filings for Q4 2025.